Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) CEO Bruce C. Cozadd sold 7,301 shares of the firm’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $154.31, for a total value of $1,126,617.31. Following the sale, the chief executive officer now directly owns 354,311 shares in the company, valued at approximately $54,673,730.41. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Jazz Pharmaceuticals Trading Up 1.7 %
Shares of NASDAQ:JAZZ opened at $153.72 on Friday. Jazz Pharmaceuticals plc has a 52-week low of $117.64 and a 52-week high of $169.98. The company has a market capitalization of $9.60 billion, a P/E ratio of -180.84, a price-to-earnings-growth ratio of 1.26 and a beta of 0.69. The company has a 50-day simple moving average of $153.10 and a 200 day simple moving average of $151.63. The company has a debt-to-equity ratio of 1.66, a quick ratio of 2.06 and a current ratio of 3.39.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) last issued its earnings results on Wednesday, May 4th. The specialty pharmaceutical company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.13. The business had revenue of $813.72 million during the quarter, compared to the consensus estimate of $853.73 million. Jazz Pharmaceuticals had a negative net margin of 1.49% and a positive return on equity of 24.44%. Jazz Pharmaceuticals’s revenue was up 33.9% on a year-over-year basis. During the same period last year, the business posted $3.42 EPS. Sell-side analysts forecast that Jazz Pharmaceuticals plc will post 14.74 earnings per share for the current year.
Institutional Investors Weigh In On Jazz Pharmaceuticals
Analysts Set New Price Targets
JAZZ has been the subject of a number of research reports. SVB Leerink increased their target price on Jazz Pharmaceuticals from $200.00 to $210.00 and gave the stock an “outperform” rating in a report on Thursday. Cowen raised their price objective on Jazz Pharmaceuticals from $200.00 to $225.00 in a report on Thursday, May 5th. BMO Capital Markets raised their price objective on Jazz Pharmaceuticals from $185.00 to $188.00 and gave the company an “outperform” rating in a report on Thursday. Morgan Stanley raised their price objective on Jazz Pharmaceuticals from $174.00 to $187.00 and gave the company an “equal weight” rating in a report on Thursday. Finally, Cowen raised their price objective on Jazz Pharmaceuticals from $200.00 to $225.00 in a report on Thursday, May 5th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $203.69.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.
- Get a free copy of the StockNews.com research report on Jazz Pharmaceuticals (JAZZ)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.